Kornimate/medical-research-clean huggingface dataset:
resilience intervention for older, hiv-infected women

Conditions: Resilience, Psychological

Summary: the goal of this study is to refine and pilot the relaxation response resiliency (3rp) intervention for women age 50 and over who are living with hiv, a group especially burdened by stressors related both to aging and living with chronic disease. the investigators will adapt the 3rp resiliency intervention to the needs of this population and conduct preliminary testing of the group intervention via an open pilot study.

overview. participants will be women living with hiv (n=up to 40) age 50 or over. women will be recruited from the boston area. based on the investigators' qualitative work, the investigators will deliver an adapted version of the 3rp resiliency intervention to groups of 5-8 hiv-infected women age 50 and over. the 3rp intervention will consist of 8-10 weekly sessions of 90 minutes each focused on skills training to build and enhance resilience. the investigators will conduct baseline and post-treatment quantitative assessments, in addition to individual exit interviews to solicit feedback on the intervention. these data will be used to inform the design of a future randomized pilot study. study procedures. participants (n = up to 40) will be hiv-infected women age 50 or over . participants will be recruited via study flyers (posted in the infectious disease clinics at local hospitals and in the waiting areas of boston area community organizations) and provider referral. once an individual expresses interest in the study, a research assistant will screen that individual to assess study eligibility criteria. individuals who meet inclusion criteria will be invited to sign informed consent and complete an in-person baseline assessment. participants will then complete the intervention (described below), a post-treatment assessment, and an individual in-depth exit interview to provide feedback on their experience in the study. 3rp intervention: once enrolled in the study, participants will complete weekly group sessions of the 3rp intervention. sessions will focus on developing an understanding of stress sources and physiology, and on developing a regular practice of eliciting the relaxation response (rr) and learning cognitive behavioral and positive psychology skills to enhance resiliency to long-term stress. participants will be encouraged to practice skills (rr practice, thoughts records to learn adaptive thinking) between group sessions.

Eligibility criteria:
inclusion criteria: * biologically born women who endorse a female identity * hiv-infected * age 50 or older * english speaking exclusion criteria: * presence of an active (i.e. untreated) and interfering psychiatric disorder (e.g., bipolar disorder, schizophrenia, substance abuse) * have participated in a structured cognitive behavioral therapy and/or a mind-body intervention in the past year
traditional chinese medicine for complications in critically ill patients

Conditions: Critically Ill Patients

Summary: the purpose of this study was to examine the impact of chinese medicine on common problems in intensive care units.

introduction: intensive care unit is a special department in the health care facility. although with highly development of modern medicine nowadays, the average mortality rate in intensive care unit is still around 7 to 20 %. there are a few tricky problems that intensivists and intensive care nurses faced very often, including intensive care unit delirium, arrythmia and poor digestion problem that will all affect the mortality and morbidity rate of critical care patients. traditional chinese medicine can possibly provide a series of interventions that can alleviate those conditions. methods: a randomized control trial will examine the effect of traditional chinese medicine interventions vs. routine intensive care unit care. the patients will be randomly divided 1:1 into one of two groups. a total of 80 intensive care patient will have to meet the following criteria: age 20-90, two or less inotropic medicine use. interventions such as: chinese herbal medicine decoction, acupuncture, laser acupuncture, chinese tuina massage, herbal medicinal cake applied on acupoint, health education and diet education, will be given based on the patients needs and traditional chinese medicine doctor decision. the main outcomes will be the incidence of arrythmia, delirium, and poor digestion and the severity of pain. the investigators will also record intensive care unit mortality, intensive care unit stays and hospital days.

Eligibility criteria:
inclusion criteria: * age 20-90 * newly intensive care unit admission (\<48 hours) * two or less inotropic medicine prescribed exclusion criteria: * clinically unstable: receiving more than inotropic agents. * coagulopathy: prolong prothrombin time、activated partial thromboplastin time more than 4 times

Keywords: traditional chinese medicine, intensive care,
dietary fiber mixture in constipated pediatric patients

Conditions: Constipation

Summary: the purpose this study was to to evaluate the therapeutic effect of a fibers mixture in the treatment of chronic constipation and on the colonic transit time in children.

in spite of an increase in the consumption of fibers being indicated for the treatment of constipation, few clinical trails have evaluated its efficiency. in the majority of prior studies only the effect of a single type of fiber was evaluated. each type of fiber presents a particular characteristic, which determines its action mechanism and performance in different parts of the colon. therefore, theoretically, greater effectiveness could well be observed when different types of fibers are associated into a single product for fiber supplementation. a randomized, parallel, double-blind, controlled was performed to evaluate the effect of a dietary fiber mixture in constipated pediatric patients. children aged between 4 and 12 years were included in the study and the initial diagnosis of functional chronic constipation was made in accordance with the rome iii criteria. the children having attended the pediatric gastroenterology ambulatory of the federal university of sao paulo and the santa casa de misericórdia hospital in sao paulo city. all of the children were undergoing constipation maintenance treatment with the use of a laxative in a dosage less than 1.0 ml/kg for milk of magnesia, mineral oil or lactulose or less than 0.5 g/kg for polyethylene glycol 3350.

Eligibility criteria:
inclusion criteria: * children aged between 4 and 12 years; * maintenance treatment using low dose of laxative; * a family with the socio-economic culture that would make it possible to carry out the procedures of the study's protocol. exclusion criteria: * children with organic cause constipation such as hirschsprung disease, cerebral paralysis, anorectal and spinal medulla abnormalities and metabolic illnesses; * the regular use of a fiber supplement during the 4 weeks prior to admission; * the use of medications that would cause constipation; * absence of a fixed or mobile telephone in order to make contact.

Keywords: dietary fiber clinical trial constipation children
adding bismuth to rabeprazole-based first-line triple therapy does not improve the eradication of helicobacter pylori

Conditions: Helicobacter Pylori Infection

Summary: this randomized controlled study aimed to evaluate whether adding bismuth to the standard first-line triple therapy could improve the eradication rate of helicobacter pylori (h. pylori). a total of 162 patients with h. pylori infection were randomly assigned to either the 7-day triple therapy group (n = 81) or the bismuth plus triple therapy group (n = 81). the triple therapy (rak) contained the twice-daily dosage of rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg. in the rbak group, bismuth subcitrate 360 mg twice daily was added to the rak regimen.

once confirmed with h. pylori infection and having signed the informed consent, participants were randomly assigned to either the standard triple-therapy group (rak: rabeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg, all twice daily for 7 days) or the bismuth plus standard triple-therapy group (rbak: rabeprazole 20 mg, bismuth subcitrate 360 mg, amoxicillin 1 g and clarithromycin 500 mg, all twice daily for 7 days). a computer-generated random number was chosen for randomization. the patients and physicians were not blinded to the therapy assigned. after completion of h. pylori eradication therapy, participants were asked to come back for collection of the information on any adverse event of drug compliance. in order to avoid false negative results, they were also asked to have a 4-week proton pump inhibitor, antibiotic and bismuth washout period before further examination of h. pylori status. the second endoscopy with rapid urea test, histology and culture or 13 c-urea breath test (ubt) for those who refused endoscopic exams was carried out at the end of the washout period. those who did not return to confirm their h. pylori status were deemed as treatment failure in intention-to-treat (itt) analysis.

Eligibility criteria:
inclusion criteria: 1. male or non-pregnant female aged more than 20 y/r 2. h.pylori-infected 3. mental and legal ability to give a written informed consent exclusion criteria: 1. allergy to any drug in the study 2. prior gastric surgery, severe concomitant diseases (e.g., decompensate liver cirrhosis, uremia, gastric cancer) 3. previous h. pylori eradication therapy 4. pregnancy or lactation.
non-inferiority of belotero® basic versus juvéderm® ultra 3

Conditions: Physiological Stress; Disorder of Aging; Skin Diseases; Wrinkles; Nasolabial Folds

Summary: this study will investigate the non-inferiority of belotero® basic versus juvéderm® ultra 3 in the treatment of nasolabial folds


Eligibility criteria:
inclusion criteria: * subject with bilateral, symmetrical nlf and wish for correction. documented severity of nlf score 2 or 3 at screening on the merz wrinkle severity rating scale ii exclusion criteria: * any severe or uncontrolled systemic disease (e.g. cardiac, renal, pulmonary, hepatic, or gastrointestinal). subject suffering from diabetes mellitus, autoimmune and rheumatic diseases, clinically relevant coagulation disorders, recurrent angina, or severe psychic, neurological or mental disease * history of malignancy within the last 5 years before the study * infection, inflammations or active dermatological disease in the face
application of transbronchial cryobiopsy in the diagnosis of progressive pulmonary fibrosis

Conditions: Pulmonary Fibrosis; Transbronchial Cryobiopsy

Summary: the goal of this clinical study is to learn about the diagnostic effectiveness, safety, and influencing factors of transbronchial cryobiopsy（tblc）in progressive pulmonary fibrosis. the main question it aims to answer are: • determine the prognosis, health economics, and therapeutic strategy changes of patients with tblc retrograde malleable pulmonary fibrosis. participants will be randomly divided into two groups, and received tblb or tblc.


Eligibility criteria:
inclusion criteria: patients with ppf, ≥18 years of age, unclassified ild, hrct ≤3 months, forced vital capacity (fvc)≥50% predicted value, pulmonary carbon monoxide diffusion (dlco)≥35% predicted value, echocardiography ≤12 months, estimated pulmonary systolic blood pressure ≤40 mmhg, body mass index (bmi)≤35 kg/m2. exclusion criteria: patients with platelet counts below 50,000×109/l or international normalized ratio of prothrombin time (inr) above 1.5 are not eligible for tblc
platelet activation and circadian rhythms of clotting-fibrinolysis factors in patients with sleep apnea syndrome

Conditions: Sleep Apnea; Cardiovascular Diseases

Summary: the objective of the study is to define and compare clotting- fibrinolysis patterns, platelet function markers and endothelial dysfunction in patients with sahs before and after treatment and normal controls age and weight matched.

the hypothesis of the study is the following: patients with sleep apnea-hypopnea syndrome have higher risk of cardiovascular mortality during the night. respiratory alterations (hypoxia, hypoxia- reoxygenation) that these patients suffer during the sleep may induce modifications in platelet function, clotting-fibrinolysis factors and endothelial function, that may accelerate cardiovascular events during the night design: prospective and controlled study methods: 20 sahs patients and 20 controls will be studied. the study includes: a) medical history; b) anthropometric variables (weight, height, body mass index, waist-hip ratio); c) sleepiness tested by epworth scale; d) conventional polysomnography (psg); e) testing every 4 hours for a 24 hours period: clotting-fibrinolysis factors (factor v, vii, viii; c and s protein, plasminogen tissular activator (t-pa) and inhibitor of plasminogen activator (pai-1); platelet activation markers (cd62, cd63 and gpiib/iiia) and endothelial dysfunction markers (endothelins, nitrites/nitrates and asymmetrical dimethyl-arginine); f) basic biochemical profile and hemogram. patients will be revaluated after 6 months of cpap treatment.

Eligibility criteria:
inclusion criteria: * apnea-hypopnea index \> 15 exclusion criteria: * presence of any chronic disease * presence of cardiovascular disease * refusal to sign informed consent * drug addiction and/or alcoholism * any medication two weeks before

Keywords: sleep apnea clotting- fibrinolysis patterns platelet function markers endothelial dysfunction
topical timolol for infantile hemangioma in early proliferative phase

Conditions: Hemangioma

Summary: infantile hemangioma (ih) is the most common benign vascular tumor in pediatric population. oral propranolol is the treatment of choice for complicated hemangiomas. topical timolol, a non-selective beta-blocker, is an emerging treatment which has been reported to be effective and safe for the treatment of ih, especially for superficial hemangiomas. investigators hypothesize that treatment with topical timolol in the first two months of life, before the proliferative phase or in early proliferative phase, may prevent from further growing and the need to treat with oral propranolol.

a multicentric, randomized, double-blind, placebo-controlled, phase ii clinical trial to evaluate the efficacy and safety of 0.5% timolol maleate solution for the early treatment of infantile hemangioma. patients with less of 60 days of life with focal or segmental hemangiomas, superficial, mixed or abortive will be treated with topical timolol 0.5% twice a day for 24 weeks. changes in lesion size, color and thickness will be evaluated from photographs taken at 2,4,8,12,24 and 36 weeks. vital signs and side effects will be recorded at each visit. response to treatment will be evaluated by a blinded investigator in a semiquantitative scale (complete resolution, improve, stabilization, worsening).

Eligibility criteria:
inclusion criteria: * written informed consent for study participation and the use of the patient's photographs from the patient's parent(s) or guardian(s), * the patient is between 10 and 60 days of age at the time of enrollment, * the patient should have: * at least one focal or segmental hemangioma, mixed or superficial, present anywhere on the body of at least 0.3 cm of minimum diameter and not greater of 5 cm. * abortive or minimal growth hemangioma * infantile hemangioma precursors exclusion criteria: * patients \> 60 days of age * complicated hemangiomas (life-threatening, function-threatening, or ulcerated) * children who have previously received systemic, intra-lesional or topical corticosteroids, imiquimod, vincristine, alpha-interferon, propranolol or other beta blockers, pdl laser. * patients with phaces, lumbar, sacral or pelvis syndrome. * internal involvement hemangiomas (liver, gi tract, larynx) * children with a personal history of asthma or cardiac conditions that may predispose to heart block. * children with congenital birth defects * children with cancer (leukemia, sarcoma, neuroblastoma, retinoblastoma) * children with a history of hypersensitivity to beta blockers or excipients.
is thoracic paravertebral block a better option than conscious sedation for prfa of liver tumors

Conditions: Liver Tumor

Summary: percutaneus radiofrequency ablation (rfa) of liver tumors causes acute pain during the periooperative setting. in order to facilitate tumor access, patient should collaborate with a surgeon during the procedurę, therefore should be conscious. this study aims to assess the impact of a single shot thoracic paravertebral block (tpvb) on a patient's haemodynamic stability, patient's and operator's comfort and satisfaction during the operation and analgesia in the post-operative period.

high temperatures used during the percutaneus radiofrequency ablation (prfa) of liver tumors can cause acute pain in the perioperative setting. in order to facilitate tumor exposure and access, patient should collaborate with a surgeon during the procedurę, therefore should be conscious. it is mandatory to provide an adequate acute postoperative pain control for our patients. this prospective randomized, single center study was approved by the bioethics committee at the university of warmia and mazury in olsztyn, (poland) under the resolution no. 46/2017.

Eligibility criteria:
inclusion criteria: * patients with primary liver tumor (hcc) * patient scheduled for an elective surgery * tumor diameter) \<5 cm two tumors \<3cm * age \>18 years * physical state 1,2 or 3 of the american society of anesthesiology (asa) exclusion criteria: * asa iv and v * thrombocytopenia (\<40x10 \^ 9 / l) * severe cirrhosis (child-pugh c classification) * history of psychiatric/cognitive disease * patients who do not give informed consent * patients with contraindications or history of hypersensitivity to local anaesthesia drugs * history of chronic pain, chronic opioid use (\> 3 months)

Keywords: paravertebral block anaesthesia analgesia regional anaesthesia pain patient satisfaction patient comfort operator satisfaction
effect of upper-body rowing on cardiometabolic risk in spinal cord injured wheelchair users

Conditions: Spinal Cord Injuries; Exercise Training

Summary: this randomized controlled trial will determine the effects of 12-weeks of wheelchair user-modified upper-body rowing on both traditional cardiometabolic risk factors in sci manual wheelchair users.

this randomized controlled trial aims to determine the effects of 12-weeks of wheelchair user-modified upper-body rowing on both traditional (insulin resistance, obesity, dyslipidemia (including low hdl-c and elevated tg and blood pressure) and novel (inflammatory status, autonomic nervous system function, vascular structure and function, and cardiorespiratory fitness level) cardiometabolic risk factors in sci manual wheelchair users. as secondary objectives, this trial will investigate the effects of the exercise intervention on free-living physical activity, shoulder pain, and indices of quality of life. men and women, aged 18-65 years; chronic sci (≥1 year since injury); individuals with sufficient sparing of arm function to participate in upper-body rowing; using a manual wheelchair as a primary tool for mobility will be included in the trial. the exercise training will be conducted as wheelchair-modified upper-body ergometer rowing. the training will be performed for up to 30 min, 3 times per week with moderate-to-vigorous intensity, with at least one rest day between sessions. outcome measurements will be performed immediately before (baseline), after (post) 12 weeks of training, and 6 months after the termination of the intervention period (follow up). this approach allows for assessment of the short term effects of exercise training as well as any residual effects from the training intervention on cardiometabolic risk, shoulder pain, indices of quality of life, and free-living physical activity

Eligibility criteria:
inclusion criteria: * 18-65 years; * chronic sci (≥1 year since injury) * individuals with sufficient sparing of arm function to participate in upper-body rowing (i.e. as a minimum excluding individuals with complete sci at or above c5) * using a manual wheelchair as a primary tool for mobility. exclusion criteria: * individuals who regularly engage in \>150 min/week of moderate-to-vigorous intensity physical activity * have received a cortisone injection in the shoulder within the last four months * have had shoulder injury within the previous year * known medical issues (urinary tract infections, cardiovascular contraindications for exercise testing, and pressure sores) * diagnosed diabetes or any endocrine, heart, kidney, liver disease or any other disease that may limit the ability to perform exercise.
acute kidney injury after cardiac surgery

Conditions: Acute Kidney Injury

Summary: the investigators seek to determine whether a reduced preoperative renal functional reserve predicts postoperative acute kidney injury in patients with normal estimated glomerular filtration rates undergoing elective cardiac surgery.

although acute kidney injury (aki) frequently complicates cardiac surgery, methods to determine aki risk in patients without underlying kidney disease are lacking. renal functional reserve (rfr) can be used to measure the capacity of the kidney to increase glomerular filtration rate under conditions of physiological stress and may serve as a functional marker that assesses susceptibility to injury. the investigators seek to determine whether a reduced preoperative rfr predicts postoperative aki in patients with normal estimated glomerular filtration rates undergoing elective cardiac surgery. all centres will measure rfr with creatinine clearance, except university hospital giessen where in addition iohexol plasma-clearance will be used.

Eligibility criteria:
inclusion criteria: 1. subjects older than 18 years 2. subjects undergoing elective cardiac surgery (with or without cardiopulmonary bypass) 3. subjects with an estimated gfr ≥60 ml/min/1.73 m2 (ckd-epidemiology collaboration equation) 4. subjects who signed informed consent forms exclusion criteria: 1. preexisting acute kidney injury (as determined by all available serum creatinine values from hospital and outpatient medical records within the previous 90 days) 2. chronic kidney disease ≥ stage iii (kdigo) 3. subjects undergoing transcatheter aortic valve implantation (tavi) 4. pregnancy 5. solitary kidney 6. diabetes mellitus type 1 7. recent cardiac arrest (within last 3 months) 8. liver failure or cirrhosis 9. total parenteral nutrition 10. hemoglobin \<11 g/dl 11. sepsis 12. history of malabsorption, chronic inflammatory bowel disease, short bowel, or pancreatic insufficiency 13. transplant donor or recipient 14. active autoimmune disease with renal involvement 15. rhabdomyolysis 16. prostate hypertrophy with international prostate symptom score ≥20 17. active neoplasm 18. decompensated heart failure / inability to pause angiotensin-converting enzyme inhibitors or angiotensin ii receptor blockers minimum 2 days before protein load 19. known iodine allergy (exclusion criteria only for those centres who use iohexol plasma clearance for determination of gfr) 20. tsh \<0.3 µu/l (exclusion criteria only for those centres who use iohexol) 21. subjects who received intravenous radiocontrast agents within the 72 hours before the protein load 22. subjects who received nsaids within 48 hours before the protein load

Keywords: protein load cardiac surgery